Stock listing

NASDAQ:AVIR Atea Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Atea Pharmaceuticals, Inc.

Follow Atea Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AVIR

$4.39 USD +0.07 (+1.6%)

Close on Oct 19, 2026

Since Jul 6, 2026 -9.9% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$4.17 – $4.42 USDOct 19, 2026
Volume
390,038 sharesOct 19, 2026
Market value
$352.1M USDAt the close on Oct 19, 2026 · price × 80.20M shares outstanding
Atea Pharmaceuticals, Inc. logo
Ticker
NASDAQ:AVIR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Atea Pharmaceuticals (NASDAQ:AVIR) Q2 2026 Earnings Call

    Wed, Aug 12, 2026 · 4:30 PM ET

    Watch Transcript

  • Atea Pharmaceuticals (NASDAQ:AVIR) Q1 2026 Earnings Call

    Tue, May 12, 2026 · 4:30 PM ET

    Watch Transcript

  • Atea Pharmaceuticals (NASDAQ:AVIR) Q4 2025 Earnings Call

    Thu, Mar 05, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 8, 2026

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Aug 5, 2026

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Jul 28, 2026

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Jul 14, 2026

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Jun 25, 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

May 27, 2026

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

May 13, 2026

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026

May 5, 2026

All Atea Pharmaceuticals, Inc. news

Decks

Atea Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 104 in all · newest Sep 8, 2026 · oldest 2020
Calls
19 calls with a replay · 19 with a transcript · latest Aug 12, 2026
Decks
11 decks · latest Aug 12, 2026

Where Atea Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AVIR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AVIRBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Atea Pharmaceuticals, Inc.